ICMR to monitor Hyderabad firm's work on anti-Zika vaccine

Image
Press Trust of India Hyderabad
Last Updated : Mar 03 2016 | 10:02 PM IST
The Indian Council of Medical Research (ICMR) today said it would closely monitor the proposal made by city-based Bharat Biotech for developing a vaccine for the Zika virus, which has emerged as a serious global health threat.
"Bharat Biotech has two proposals or ideas for development of a vaccine. One with an inactivated Zika virus and the other is a recombinant... It's a proposal. They have done some early work. In the next few months, we will closely monitor and work with them and see the progress. At the moment, we do not have a vaccine candidate," ICMR Director- General Soumya Swaminathan told reporters here.
Swaminathan is here to attend the ongoing 17th International Congress on Infectious Diseases.
When pointed out that it may take several years for the vaccine to come out, she said the process of developing a substance has to go through the regulatory steps, though the process can be expedited with various stakeholders joining the endeavour and in the Public Private Partnership (PPP) mode.
"I think now, because of the recognition that this is important and also the PPPs and various bodies agreeing to come together and work, I think if there is a promising vaccine lead, then we can get many different partners involved and take it forward more rapidly. Of course, it still has to go through the regulatory steps," she said.
Medical experts are now suggesting the idea of 'vaccine platforms' to beat the delays, Swaminathan said.
"People are now talking about having platforms, create a vaccine platform. That's one of the advantages Bharat Biotech had. He (the company) had already been working on a Chikungunya vaccine.
"Because, Zika virus is quite similar, if he is able to adopt that platform, I think doing more basic research on vaccine platforms is probably equally important. Of course, it takes time... But, I think the timelines are shrinking," she said.
The most common symptoms of Zika virus disease, caused by mosquito bites, are fever, rash, joint pain and red eyes. There's no vaccine or specific treatment for the infection, known as Zika fever.
(REOPENS BES35)
Swaminathan said surveillance and testing of people is being done to deal with Zika at present, besides looking at the issue of developing a vaccine.
"For Zika, at the moment, what we are doing is surveillance. Making sure that we equip our labs to be able to test for Zika. We want to find out if there is any Zika circulating. So, we are testing people who present with fever, just like a dengue but a dengue negative. We have not found any case so far, but we will continue this exercise," she said.
The ICMR hopes to get a live virus so that government labs can start working on it, she said.
"We want to develop our own diagnostics. For that, we are hoping we can get the live virus... So that our labs can start working on it. Third is, we will monitor the progress of this vaccine candidate that Bharat Biotech has. At any stage, if government support, help is needed to take it forward..." she added.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 03 2016 | 10:02 PM IST

Next Story